Abstract:Background A number of clinical trials evaluated the efficacy and adverse effects of oral propranolol in the treatment of infantile hemangioma (IH), but the treatment has not yet been standardized. This meta-analysis aims to reevaluate the efficacy and adverse effects of oral propranolol in comparative studies and to provide a reliable basis for clinical administration in the therapy for IH. Methods Data were obtained from PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure and Wanfang database, from inception to December 1st, 2018. The pooled risk ratios (RR) with 95% confidence intervals (95% CI) were calculated and used to evaluate the effect size. The meta-analysis was performed using the random-effects model due to heterogeneity between the studies. The Cochrane Collaboration 6 aspects of bias, methodological index for non-randomized studies and the Newcastle–Ottawa Scale were used to assess the risk for bias. Sensitivity analysis, publication bias and subgroup analysis were performed. Results Eighteen unique studies involving 2701 unique children were included in the analysis. The response rate was reported in 18 trials, which compared oral propranolol with other treatments. The heterogeneity was statistically significant ( P < 0.00001, I 2 = 95%). The difference in the response rate was statistically significant (RR = 1.40, 95% CI 1.13–1.75) while compared with the controls. However, no significant difference in the adverse events rate (RR = 0.78, 95% CI 0.45–1.34) and relapse rate (RR = 1.45, 95% CI 0.66–3.16) were found. Otherwise, the subgroup analysis indicated that the RR was 1.64 (95% CI 0.24–11.36) for low-dose propranolol (1 mg/kg/day), 1.42 (95% CI 1.12–1.80) for medium dose (2 mg/kg/day) and 1.46 (95% CI 1.17–1.82) for high dose (3 mg/kg/day), but the high dose had higher adverse events rate than medium dose, with 3.60% and 86.22%, respectively. The effectiveness of propranolol therapy among cases of treatment duration less than 6 months (RR = 1.24, 95% CI 1.05–1.47) was inferior to that of treatment duration greater than or equal to 6 months (RR = 1.46, 95% CI 1.11–1.92). Conclusions This meta-analysis reveals that oral propranolol is superior to other treatments in improving response rate of IH and can be used as the first-line therapy for IH children. A dosage of 2 mg/kg/day propranolol orally may be a good choice for IH. However, further studies are essential.

Treatment of Proliferative Hemangiomas with High Dose of Systemic Corticosteroid

The Diagnosis and Treatment for Infant Hemangiomas

Effect of Combined Low-Dose Oral Prednisone with Beta-Adrenergic Receptor Antagonists for Refractory Infantile Hemangiomas: Retrospective Cohort Study in 76 Patients

Infantile Hemangioma: Treatment with Short Course Systemic Corticosteroid Therapy as an Alternative for Propranolol

Evaluation on efficacy of different doses of propranolol in treatment of infantile hemangioma

Clinical Observations on Infantile Hemangiomas Treated with Low-Dose Propranolol

Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]

Propranolol in the treatment of problematic infantile hemangiomas

[An Experimental Study on the Mechanism of Therapy for Hemangioma with Glucocorticoid].

Pharmacological Therapies For Infantile Hemangiomas: A Clinical Study In 853 Consecutive Patients Using A Standard Treatment Algorithm

Injection of Triamcinolone Acetonide Acetate and Pingyangmycin for Infant Hemangioma at Privileged Sites

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

[A Prospective Study of Propranolol As First-Line Treatment for Problematic Infantile Hemangioma in China].

The efficacy of oral propranolol for infantile hemangiomas in 68 cases

A Self‐controlled Study of Intralesional Injection of Diprospan Combined with Topical Timolol Cream for Treatment of Thick Superficial Infantile Hemangiomas

Clinical efficacy of oral propranolol for the treatment of infant proliferating hemangiomas and the changes of serum VEGF

Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review

Pharmacotherapy of Infantile Hemangiomas

Intralesional Corticosteroid Injections for Infantile Hemangioma

Effects of Systemic Propranolol Treatment on Physical Growth of Patients with Infantile Hemangiomas

Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas.